Antibody Validation Methods: A Practical Guide

Antibody validation is the process of demonstrating that a specific antibody reagent reliably detects its intended target in a defined assay context. For laboratory students, technicians, researchers, and diagnostic professionals, validation is not an optional quality step but a prerequisite for generating interpretable data. Antibodies are among the most frequently used tools in basic research and clinical assays, yet no universally accepted guidelines or standardized methods exist for determining reagent validity, and commercially available antibodies may not always match their labels [7]. This article describes the principal antibody validation methods, explains how to select an appropriate strategy for a given application, and provides a practical decision framework for implementation in routine laboratory work.

At a Glance: Antibody Validation Methods and Applications

The table below summarizes the main validation methods, their typical applications, and key considerations for each approach.

Core Principles of Antibody Validation

Specificity, Selectivity, and Reproducibility

To validate an antibody, it must be shown to be specific, selective, and reproducible in the context for which it is to be used [7]. Specificity refers to the antibody's ability to bind the intended target without cross-reacting with other proteins. Selectivity describes the antibody's capacity to distinguish the target from closely related molecules, such as isoforms or post-translationally modified variants. Reproducibility means that the antibody produces consistent results within and between experiments when assay conditions are held constant.

These three properties are not intrinsic to the antibody alone. They emerge from the interaction between the antibody, the sample preparation method, the detection system, and the assay format. An antibody that performs well in Western blot may fail in immunohistochemistry because the target epitope is masked by tissue fixation. Conversely, an antibody validated for flow cytometry may not recognize its target in the denatured state used for Western blot. Validation must therefore be performed in the specific assay context where the antibody will be used.

Assay Context Determines Validation Strategy

The performance of primary antibodies is strongly influenced by assay context, and recommendations for validation and usage are unique to each type of immunoassay [19]. A validation plan for Western blot should include molecular weight confirmation and the use of orthogonal methods. A validation plan for immunohistochemistry should include tissue controls and, where possible, comparison with an independent detection method. The same antibody may require separate validation for each new application.

The Problem of Commercial Antibody Variability

For commercially available antibodies, what is on the label does not necessarily correspond to what is in the tube [7]. Vendors provide varying levels of validation, and some antibodies are sold with minimal experimental evidence supporting their claimed specificity. A study testing 24 monoclonal antibodies against SUMO proteins across multiple detection formats found several poorly specific published antibodies that cross-reacted with related family members [10]. Inconsistencies between antibodies were prevalent in their ability to detect monomeric, conjugated, and polymeric forms of the target, and the ability to detect changes across experimental conditions varied widely [10]. Researchers must be aware of these caveats when selecting antibodies for their work.

Western Blot Validation

Principles and Workflow

Western blot validation is one of the most common approaches for confirming antibody specificity. The method separates proteins by molecular weight using gel electrophoresis, transfers them to a membrane, and probes with the primary antibody of interest. A specific antibody should produce a band at the expected molecular weight of the target protein, with minimal background or additional bands.

The antibody should produce reproducible results within and between Western blotting experiments, and the observed effect should be confirmed with a complementary or orthogonal method [19]. Practical strategies for validation include testing the antibody against lysates from cells or tissues known to express the target, comparing with lysates where the target has been knocked down or knocked out, and using recombinant protein standards containing the antigen sequence.

Recombinant Protein Standards

Quantitative Western blot analysis can be improved by using purified recombinant protein standards that contain the antigen. For membrane proteins such as G protein-coupled receptors, full-length recombinant proteins often aggregate and precipitate in aqueous solution because of their hydrophobic transmembrane domains [22]. This problem can be overcome by engineering soluble recombinant fragments of the receptor that contain the antigen sequence. In one design, researchers generated soluble and stable recombinant constructs containing much of the human cannabinoid CB1 receptor C-terminal tail for use as standard and negative control in quantitative Western blot analysis [22]. Estimated receptor densities obtained by quantitative Western blot were of the same order of magnitude but slightly higher than values obtained by radioligand saturation binding assays [22]. This approach provides a radioactivity-free alternative for quantitative analysis of receptor expression.

Diagnostic Western Blot Validation

Western blot has been validated as a diagnostic method for infectious disease serology. In a study validating a Western blot for Histoplasma capsulatum antibody detection, the test showed sensitivity of 94.9 percent, specificity of 94.1 percent, positive predictive value of 94.1 percent, negative predictive value of 94.9 percent, and accuracy of 94.5 percent [23]. The study also demonstrated that nitrocellulose strips sensitized with deglycosylated histoplasmin antigen remained viable for at least 5 years after preparation [23]. This finding supports the use of Western blot in public health settings where laboratory facilities are relatively limited.

Western blot has also been optimized for analyzing dried blood spot samples in HIV serodiagnosis. In a performance validation study, all dried blood spot samples showed the band pattern compatible with the criterion for HIV positivity established by the Ministry of Health [24]. The reciprocal relationship between antibody reactivity of dried blood spot samples and the respective plasma samples was investigated to validate the testing approach [24]. The easy collection, transportation, and storage of dried blood spot samples supports the use of this technique for epidemiological surveys.

Limitations of Western Blot Validation

Western blot validation has inherent limitations. The method uses denatured proteins, so an antibody that works in Western blot may not recognize the native conformation of the target in living cells or tissue sections. Additionally, the presence of a band at the expected molecular weight does not prove that the band is the intended target, because other proteins may comigrate at the same molecular weight. Confirmation with an orthogonal method, such as mass spectrometry or an independent antibody raised against a different epitope, strengthens the validation.

Immunoprecipitation Validation

Principles and Workflow

Immunoprecipitation uses an antibody to capture its target protein from a complex mixture, such as a cell lysate. The captured protein is then analyzed, typically by Western blot or mass spectrometry. Immunoprecipitation validation requires demonstrating that the antibody selectively enriches the target and that the enrichment is not due to nonspecific binding to the antibody or to the beads used for capture.

A standard validation workflow includes a beads-only control, where lysate is incubated with beads in the absence of antibody, and an isotype control, where an unrelated antibody of the same immunoglobulin class is used. The target should be present in the immunoprecipitated sample but absent or greatly reduced in the controls. Confirmation by Western blot with a second antibody directed against a different epitope provides additional evidence that the captured protein is the intended target.

Applications and Limitations

Immunoprecipitation is particularly useful for studying protein-protein interactions and for enriching low-abundance proteins before downstream analysis. The method requires native conditions, so the antibody must recognize its epitope in the folded protein. Some antibodies that work well in Western blot fail in immunoprecipitation because the epitope is buried in the native structure. Conversely, some antibodies that work in immunoprecipitation fail in Western blot because the epitope is destroyed by denaturation.

Immunohistochemistry Validation

Principles and Workflow

Immunohistochemistry localizes a target protein within tissue sections using an antibody and a detection system that produces a visible signal. Validation for immunohistochemistry requires demonstrating that the antibody produces specific staining in tissues known to express the target and no staining in tissues known to lack the target. Positive and negative tissue controls should be included in every staining run.

The validation algorithm for immunohistochemistry and quantitative immunofluorescence should include testing the antibody across a range of fixation conditions, antigen retrieval methods, and antibody dilutions [7]. Fixation can cross-link proteins and mask epitopes, while antigen retrieval can unmask epitopes but may also increase background staining. The optimal conditions must be determined empirically for each antibody and tissue type.

The Challenge of Low-Expression Targets

Immunohistochemistry validation becomes more challenging when the target is expressed at low levels. The repurposing of a legacy HER2 immunohistochemistry assay to identify HER2-low breast cancers illustrates this problem. The legacy assay was originally developed to identify tumors with HER2 overexpression resulting from gene amplification, which leads to substantially higher receptor expression than in low or ultralow expression tumors [17]. Applying the assay to distinguish HER2-low and HER2-ultralow tumors from truly HER2-negative tumors represents a fundamentally different biological and clinical purpose, yet the assay's analytical and clinical validation for this new purpose remains incomplete [17]. Critical gaps include the lack of established analytical sensitivity and specificity for identifying 1+ HER2 cases, poor reproducibility of pathologist scoring at low HER2 levels, and the absence of alternative methodologies for orthogonal validation [17].

This example demonstrates that increased analytical sensitivity does not automatically translate to clinical utility. Validation must be fit for purpose, meaning that the assay must be shown to perform adequately for the specific clinical or research question it is intended to address.

Flow Cytometry Validation

Principles and Workflow

Flow cytometry detects and quantifies proteins on the surface or inside individual cells in suspension. Validation for flow cytometry requires demonstrating that the antibody specifically binds its target and that the measured signal reflects the true expression level of the protein.

Controls for flow cytometry validation include isotype controls, which use an antibody of the same immunoglobulin class with no specificity for the target, and fluorescence-minus-one controls, which contain all fluorophores except the one being measured. These controls help distinguish specific signal from background fluorescence and spectral overlap.

For intracellular targets, the validation must also account for the fixation and permeabilization steps used to make the target accessible to the antibody. These steps can affect epitope availability and may require optimization for each antibody.

Limitations of Flow Cytometry Validation

Flow cytometry measures the intensity of fluorescence, which is only indirectly related to the number of target molecules per cell. The relationship between fluorescence intensity and protein abundance depends on the antibody affinity, the fluorophore-to-antibody ratio, and the instrument settings. Quantitative flow cytometry requires calibration with beads containing known numbers of fluorophore molecules.

ELISA Validation

Principles and Workflow

Enzyme-linked immunosorbent assay, or ELISA, quantifies soluble antigens or antibodies in complex samples such as serum, plasma, or culture supernatant. Validation of an ELISA requires demonstrating that the assay accurately and reliably measures the target across the intended range of concentrations.

The development and qualification of an indirect ELISA for detecting Nipah virus glycoprotein-specific IgG antibodies in human serum provides an example of systematic assay validation [18]. The assay was optimized for antigen concentration, blocking conditions, and serum dilution, and its performance was evaluated using convalescent human sera along with the World Health Organization International Standard for anti-Nipah virus antibodies [18]. Analytical validation included assessments of sensitivity, specificity, precision, linearity, and detection limits [18]. The assay demonstrated 100 percent sensitivity and specificity relative to reference sera, with intra-assay coefficients of variation ranging from 0.36 percent to 5.73 percent and inter-assay variation of 4.16 percent [18]. The lower limit of detection was 0.51 IU/mL and the lower limit of quantification was 0.98 IU/mL [18]. Calibration against an international standard supports the applicability of the assay for standardized antibody measurement [18].

Key Validation Parameters

The key validation parameters for ELISA include sensitivity, which is the lowest concentration of target that can be reliably detected, and specificity, which is the ability to measure the target without interference from other sample components. Precision refers to the closeness of agreement between replicate measurements, and linearity refers to the ability to obtain results that are directly proportional to the concentration of the target in the sample.

The limit of detection is the lowest concentration that can be distinguished from a blank, while the limit of quantification is the lowest concentration that can be measured with acceptable precision and accuracy. These parameters must be established for each assay using appropriate statistical methods.

ELISA for Mycoplasma Detection

Nucleic acid amplification technology has been developed as an alternative to culture methods for detecting Mycoplasma contamination in biological products [15]. The culture method and indicator cell culture method exhibit low sensitivity and are incapable of detecting low-concentration contamination, and the detection period may extend up to 28 days [15]. A nucleic acid amplification method using multiplex quantitative PCR with fluorescent probes was validated with a limit of detection of 10 CFU/mL, and the method met predefined requirements for sensitivity, specificity, and robustness [15]. This example illustrates how validation principles apply across different assay formats.

Surrogate Protein Validation Methods

MILKSHAKE and Sundae Methods

Surrogate protein methods use engineered recombinant proteins to validate antibody specificity at high resolution. The MILKSHAKE method uses a modified maltose binding protein that is enzymatically conjugated to a peptide from the chosen target, which is either modified or non-modified at the residue of interest [20]. The surety of the residue's modification status can be used to confirm antibody specificity to the target's post-translational modification [20].

The Sundae method uses a set of modified maltose binding proteins with a genetically encoded target sequence, each containing a single amino acid substitution at one position of interest [20]. With Sundae, antibodies can be evaluated for binding specificities to all twenty amino acids at a single position [20]. Combining MILKSHAKE and Sundae methods, antibody specificity can be determined at single-residue resolution [20]. These data improve evaluation of commercially available antibodies and identify off-target effects for research-use-only and therapeutic antibodies [20].

Applications for Post-Translational Modification Detection

Surrogate protein methods are particularly valuable for validating antibodies that detect post-translationally modified proteins. Knowing that an antibody's sensitivity and specificity is accurate is crucial for reliable data collection, and this certainty is especially difficult to achieve for antibodies that bind post-translationally modified proteins [20]. The MILKSHAKE and Sundae methods provide a systematic approach to confirming that an antibody recognizes the intended modification and not the unmodified protein or a different modification at the same residue.

Choosing a Validation Strategy

Decision Framework Based on Application

The choice of validation method depends on the intended application of the antibody. The table below provides a decision framework for selecting validation strategies.

Fit-for-Purpose Validation

Validation must be fit for purpose, meaning that the level of validation should match the intended use of the antibody. A research antibody used for exploratory Western blot may require less extensive validation than a diagnostic antibody used for clinical decision-making. However, even research antibodies should be validated for specificity, selectivity, and reproducibility in the context of use [7].

The concept of fit-for-purpose validation is particularly important when repurposing an existing assay for a new application. The HER2-low example demonstrates that an assay validated for one purpose, detecting HER2 overexpression, may not be adequately validated for a different purpose, distinguishing HER2-low from HER2-negative tumors [17]. The analytical and clinical validation for the new purpose remains incomplete, and the ASCO/CAP guidelines cutoffs were developed for HER2 overexpression detection and may not be the best choice for HER2-low identification without clinical validation and determination of fit-for-purpose analytical specifications [17].

Practical Implementation Steps

Step 1: Define the Intended Use

Before beginning validation, document the intended use of the antibody. Specify the assay format, the sample types, the target protein, and the expected range of expression levels. This documentation guides the selection of validation methods and controls.

Step 2: Review Available Information

Search the published literature and vendor documentation for information about the antibody. The National Center for Biotechnology Information provides access to literature resources that can help identify published validation data [5]. Note any reported cross-reactivities, recommended applications, and known limitations.

Step 3: Design the Validation Plan

Select the validation methods appropriate for the intended use. Include positive and negative controls, and plan for confirmatory experiments using orthogonal methods. Document the validation plan before beginning experiments.

Step 4: Execute the Validation Experiments

Perform the validation experiments according to the plan. Record all experimental conditions, including antibody lot number, dilution, incubation times, and detection methods. Include appropriate controls in every experiment.

Step 5: Analyze and Document Results

Analyze the validation data and document the results. Record the sensitivity, specificity, and reproducibility of the antibody in the tested context. Note any conditions under which the antibody failed to perform as expected.

Step 6: Establish Ongoing Quality Control

For antibodies used in routine assays, establish ongoing quality control procedures. Include positive and negative controls in every assay run, and monitor assay performance over time. Document any changes in antibody performance that may indicate reagent degradation or lot-to-lot variability.

Records and Measurements

Essential Documentation

Laboratory records for antibody validation should include the antibody identity, including catalog number and lot number, the validation date, the assay format, the sample types tested, the experimental conditions, and the results. The World Health Organization Laboratory Quality Management System Handbook provides guidance on documentation practices for laboratory quality management [1]. Maintaining accurate records supports reproducibility and enables troubleshooting when assay problems arise.

Performance Metrics

Quantitative validation should include measurements of sensitivity, specificity, precision, and accuracy where applicable. For diagnostic assays, sensitivity and specificity are typically calculated based on comparison with a reference standard. For research assays, validation may focus on demonstrating that the antibody detects the target in known positive samples and does not detect it in known negative samples.

Common Failure Patterns

Cross-Reactivity with Related Proteins

Antibodies may cross-react with proteins that share sequence or structural similarity with the intended target. This is a particular concern for antibodies against members of protein families, such as SUMO1 through SUMO4, where antibodies raised against one family member may cross-react with others [10]. Testing antibodies against a panel of related proteins can identify cross-reactivity.

Lot-to-Lot Variability

Antibody performance can vary between lots from the same vendor. Changes in production methods, purification procedures, or formulation can affect antibody affinity, specificity, or stability. Laboratories should test each new lot before routine use and compare its performance with the previous lot.

Epitope Masking in Fixed Tissues

Fixation can mask epitopes and prevent antibody binding in immunohistochemistry. Antigen retrieval methods can unmask epitopes but may also increase background staining. The optimal fixation and retrieval conditions must be determined empirically for each antibody and tissue type.

Inconsistent Detection of Modified Proteins

Antibodies against post-translationally modified proteins may detect the modified form in some contexts but not others. The ability to detect changes in modification across experimental conditions can vary widely between antibodies [10]. Surrogate protein methods can help identify antibodies with reliable detection of specific modifications [20].

Limitations of Antibody Validation

No Universal Standards

There are no universally accepted guidelines or standardized methods for determining the validity of antibody reagents [7]. Different vendors provide different levels of validation, and published validation data may not be available for all antibodies. Researchers must therefore conduct their own validation experiments for critical applications.

Context-Dependent Performance

Antibody performance is context dependent, and validation in one assay format does not guarantee performance in another format. An antibody validated for Western blot may fail in immunohistochemistry, and an antibody validated for flow cytometry may fail in immunoprecipitation. Each new application requires its own validation.

Resource Constraints

Comprehensive antibody validation requires time, materials, and expertise that may not be available in all laboratories. The development of validated methods for detecting Mycoplasma in biological products illustrates the resources required for method validation, including the use of reference standards and statistical analysis of replicate measurements [15]. Laboratories must balance the need for validation against available resources.

Safety and Regulatory Context

Biosafety Considerations

Antibody validation experiments may involve handling biological samples that contain infectious agents. The World Health Organization Laboratory Biosafety Manual provides guidance on safe handling of biological materials [2]. Laboratories should follow appropriate biosafety practices, including the use of personal protective equipment and containment facilities as required by the risk assessment.

Regulatory Guidance for Diagnostic Assays

Diagnostic assays that use antibodies are subject to regulatory oversight. The U.S. Food and Drug Administration Bioanalytical Method Validation Guidance provides recommendations for validating bioanalytical methods used in regulatory studies [4]. The National Center for Advancing Translational Sciences Assay Guidance Manual provides guidance on assay development and validation for translational research [3]. Laboratories developing diagnostic assays should consult the relevant regulatory guidance for their jurisdiction.

Quality Management

The World Health Organization Laboratory Quality Management System Handbook emphasizes the importance of quality management in laboratory operations [1]. Antibody validation is a component of quality management, ensuring that laboratory results are reliable and reproducible. Laboratories should integrate antibody validation into their quality management systems.

Professional Escalation Criteria

When to Seek Additional Expertise

Laboratory personnel should seek additional expertise when validation results are ambiguous or when an antibody fails to perform as expected despite troubleshooting. Situations that warrant escalation include persistent high background, unexpected band patterns in Western blot, inconsistent staining in immunohistochemistry, and poor reproducibility between experiments.

When to Consider an Alternative Antibody

If an antibody cannot be validated for the intended application after reasonable troubleshooting, consider an alternative antibody directed against a different epitope of the same target. Multiple antibodies against the same target can provide orthogonal validation, and concordant results from independent antibodies strengthen confidence in the findings.

When to Consult Regulatory Guidance

For diagnostic assays intended for clinical use, consult the relevant regulatory guidance before beginning validation. The U.S. Food and Drug Administration Bioanalytical Method Validation Guidance provides recommendations for bioanalytical method validation [4]. The World Health Organization Laboratory Quality Management System Handbook provides guidance on quality management for laboratories [1].

Frequently Asked Questions

What is the difference between antibody validation and antibody characterization?

Antibody characterization describes the physical and functional properties of an antibody, such as its isotype, affinity, and epitope. Antibody validation demonstrates that the antibody performs as intended in a specific assay context. Characterization provides information about the antibody itself, while validation provides evidence that the antibody is suitable for a particular application.

How many validation methods should I use for a new antibody?

The number of validation methods depends on the intended use of the antibody. For research applications, at least one primary validation method and one confirmatory method are recommended. For diagnostic applications, more extensive validation is typically required, including assessment of sensitivity, specificity, precision, and accuracy. The validation should be fit for purpose, meaning that the level of validation matches the intended use.

Can I use an antibody validated by the vendor without performing my own validation?

Vendor validation data can provide useful information, but it does not replace independent validation in your own laboratory. Vendor validation is typically performed under specific conditions that may differ from your assay conditions. The performance of primary antibodies is strongly influenced by assay context, and recommendations for validation and usage are unique to each type of immunoassay [19]. You should confirm that the antibody performs as expected in your specific assay.

What controls should I include in Western blot validation?

Western blot validation should include a positive control lysate known to express the target, a negative control lysate where the target is absent or reduced, a loading control antibody to confirm equal protein loading, and a secondary-only control to detect nonspecific binding of the detection antibody. Knockout or knockdown lysates provide the strongest negative controls when available.

How do I validate an antibody for detecting post-translational modifications?

Validating antibodies for post-translational modifications requires demonstrating that the antibody recognizes the modified form of the target and not the unmodified form. Surrogate protein methods such as MILKSHAKE and Sundae can confirm antibody specificity at single-residue resolution [20]. These methods use engineered recombinant proteins with defined modifications to test antibody binding.

What is the limit of detection and why is it important?

The limit of detection is the lowest concentration of target that can be reliably distinguished from a blank. It is important because it defines the sensitivity of the assay. For ELISA validation, the limit of detection is established using statistical methods based on replicate measurements of blank and low-concentration samples [18].

How often should I revalidate an antibody?

Revalidate an antibody when you change the assay format, change the sample type, or receive a new lot from the vendor. Monitor antibody performance over time using positive and negative controls in routine assays. If assay performance changes, investigate the cause and revalidate as needed.

What should I do if my antibody fails validation?

If an antibody fails validation, first troubleshoot the experimental conditions, including sample preparation, antibody dilution, incubation times, and detection methods. If troubleshooting does not resolve the problem, consider an alternative antibody directed against a different epitope of the same target. Document the failed validation and the troubleshooting steps in your laboratory records.

Related Diagnostic Guides

• Protein Detection Methods: Western Blot, ELISA, and Immunofluorescence Compared
• Flow Cytometry Immunophenotyping of Canine Lymphoma
• Western, Southern, and Northern Blotting Methods
• Flow Cytometry in Veterinary Viral Immunology
• Positive Controls in Western Blotting: Selection and Validation

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.. The Lancet. Neurology, 2021.
• Antibody validation.. BioTechniques, 2010.
• Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.. Lancet (London, England), 2017.
• Secukinumab in plaque psoriasis--results of two phase 3 trials.. The New England journal of medicine, 2014.
• SUMO Antibody Validation.. Methods in molecular biology (Clifton, N.J.), 2025.
• Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.. The Lancet. Neurology, 2017.
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.. Lancet (London, England), 2016.
• Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.. Lancet (London, England), 2012.
• Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany.. 2026.
• Establishment of Nucleic Acid Amplification Technology for the Detection of &lt,i&gt,Mycoplasma&lt,/i&gt, in Biological Products.. 2026.
• Normal ALT masks occult liver injury in young chronic hepatitis B patients: a call for early treatment intervention.. 2026.
• "HER2-Low" and the Challenge of Repurposing Legacy HER2 IHC Biomarker Assays.. 2026.
• Development and Qualification of a Nipah Virus Glycoprotein-Specific IgG ELISA for the Assessment of Human Antibody Responses.. 2026.
• Antibody validation for Western blot: By the user, for the user. Journal of Biological Chemistry, 2019.
• MILKSHAKE Western Blot and Sundae ELISA: We All Scream for Better Antibody Validation. JIM - Journal of Immunological Methods, 2023.
• Antibody validation by Western Blot SOP #012 v1. protocols.io, 2020.
• Design and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CB1 receptor density in cell membranes: an alternative to radioligand binding methods. Microbial Cell Factories, 2022.
• Validation of western blot for Histoplasma capsulatum antibody detection assay. BMC Infectious Diseases, 2016.
• Performance validation of western blot for anti-HIV antibody detection in blood samples collected on filter paper (DBS). 2017.
• Validation of method for assay of residual protein A in antibody drugs. Chinese Journal of New Drugs, 2022.
• Enhanced validation of antibodies for research applications. Nature Communications, 2018.
• Establishment and validation of an ELISA method for quantitation of 13 serotype-specific anti-pneumococcal IgG antibodies in mouse serum. Chinese Journal of New Drugs, 2014.
• Interlaboratory validation of HPAEC-PAD method for N-glycan profile analysis of monoclonal antibodies. Chinese Journal of New Drugs, 2020.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.